Skip to content

A multicenter, randomized controlled clinical trial of acupoint embedding therapy and traditional Chinese medicine tea drinking for the intervention of mild psoriasis combined with overweight

A multicenter, randomized controlled clinical trial of acupoint embedding therapy and traditional Chinese medicine tea drinking for the intervention of mild psoriasis combined with overweight

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025002460
Enrollment
Unknown
Registered
2025-12-24
Start date
2026-01-01
Completion date
Unknown
Last updated
2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psoriasis

Interventions

Acupoint Fake Thread Implantation Group:Needle acupuncture at the selected points every two weeks, without using sutures. Based on the random grouping, a third-party researcher prepared the acupunctur
Acupoint Insertion Thread Group:Acupuncture at the selected points and thread implantation are performed every two weeks. According to the random grouping situation, a third-party researcher prepares
blank control group:On the basis of conventional treatment and chronic disease management, no other interventions will be carried out except for those for research purposes.
Traditional Chinese Medicine Tea Drink Group:On the basis of conventional treatment and chronic disease management, a daily dose of tea infusion is provided. It is prepared by boiling water and then d

Sponsors

The Second Affiliated Hospital of Hunan University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 50 Years

Inclusion criteria

Inclusion criteria: a. Male or female aged 18-50 years old. b. Clinically diagnosed with plaque-type psoriasis, with TCM syndrome of blood stasis. c. The severity of psoriasis is mild, with PASI < 3 or BSA < 3%. d. Overweight, with BMI = 24. e. Fully understand the research purpose, and have a basic understanding of the effects of acupoint embedding therapy and tea drinking, as well as possible adverse reactions. f. Able to adhere to follow-up and provide true feedback. g. Informed consent, voluntary participation, and signing the informed consent form.

Exclusion criteria

Exclusion criteria: a. Within the past 1 month, received traditional systemic treatment for psoriasis (such as cyclosporine, methotrexate, acitretin, traditional Chinese medicine treatment, phototherapy, etc.) and small molecule targeted drug treatment; within the past 3 months, received biologic treatment for psoriasis. b. Has clinically significant coagulation disorders, infectious diseases, mental disorders, autoimmune diseases, malignant lesions (such as tumors), organ organic diseases, cognitive dysfunction, etc. c. Within the past 3 months, had a weight change of more than 10% or a significant change in body shape. d. Within the past 3 months, conducted continuous intervention for weight loss (such as diet control, taking weight loss tea, regular physical exercise, etc.) and accompanied by weight loss. e. History of food or drug allergies. f. Participated in other clinical studies within the past 6 months. g. During pregnancy or lactation, and planning to get pregnant in the near future. h. Unable or unwilling to comply with the intervention plan, regular hospital follow-up, blood collection and testing. i. Other situations that the researchers consider not suitable for inclusion.

Design outcomes

Primary

MeasureTime frame
Psoriasis Area and Severity Index;Body Mass Index;

Secondary

MeasureTime frame
Body Surface Area;Physician Global Assessment;Dermatology Life Quality Index;Itch VAS score;Erythrocyte sedimentation rate, C-reactive protein;Traditional Chinese Medicine Syndrome Score;waist circumference;hip circumference;Waist-to-Hip Ratio;

Countries

China

Contacts

Public ContactWang Haizhen

The Second Affiliated Hospital of Hunan University of Chinese Medicine

491476160@qq.com13873165440

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Mar 21, 2026